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A survey on Biostatisticians Serving in the 
Italian Ethics Committees
ABSTRACT 
Background: Italian ethics committees (ECs) have the responsibility for evaluating and monitoring clinical research. 
Methods: An electronic survey targeted to the biostatisticians operating in the 95 ECs in Italy, was launched in 
November 2016. Several aspects were explored such as education, job title, training in biostatistics and experience 
in the evaluation of protocols within the EC. 
Results: Seventy case report forms were returned (74%), and the response rate was highest for ECs located in 
the South (78%) and lowest in the North (51%). The biostatisticians in the respondent ECs were prevalently male, 
aged 50-60 years, with postgraduate education in medical specialties and statistics. The annual workload varied 
depending on the type of institution and geographical area, with an annual median number of protocols examined 
ranging from 80 in hospital ECs to 198 in university hospital ECs, and from 80 to 108, in the South and the Centre, 
respectively. Of these, 40% were observational study protocols. The EC biostatisticians proposed to reject 5% of 
protocols and to suspend with the request of clarification or amendments 10%. Only 61% and 79% of these opinions, 
respectively, were regarded as binding by the other EC members.
Conclusion: The biostatistician will not be able to play a significant role in the EC as long as the required skill-set 
remains vague and his/her opinion on a protocol is underrated. 
Key words: Ethics Committee; Biostatistician; Survey; REDCap 
Ileana Baldi (1), Danila Azzolina (1), Daniele Chiffi (1,2,3), Teresa Barrella (1), Matteo Martinato (1), Paola Berchialla (4),  
Dario Gregori (1) on behalf of the NEBICE (Network of Biostatisticians in the Ethics Committee) Working Group*
(1) Unit of Biostatistics, Epidemiology and Public Health, Dept. of Cardiac Thoracic and Vascular Sciences, University of Padova, Italy
(2) Universidade Nova de Lisboa, Portugal
(3) Tallinn University of Technology, Estonia
(4) Dept. of Clinical and Biological Sciences, University of Torino, Italy
(*) Paola Berchialla (University of Torino); Giovanni Corrao and Antonella Zambon (University of Milano-Bicocca); Mario Comelli and Cristina Montomoli 
(University of Pavia); Marco Ferrario and Giovanni Veronesi (University of Insubria); Elisabetta Zanolin (University of Verona); Ileana Baldi, AnnaChiara 
Frigo, Dario Gregori and Francesco Grigoletto (University of Padova); Miriam Isola (University of Udine); Giulia Barbati (University of Trieste); Roberto 
D'Amico (University of Modena and Reggio Emilia); Marco Rocchi (University of Urbino); Flavia Carle (Marche Polytechnic University); Ciro Gallo (University 
of Campania); Patrizio Pasqualetti (Fatebenefratelli Hospital, Rome); Annarita Vestri (University Sapienza); Valentina Panetta (L’altrastatistica s.r.l.); Vincenzo 
Guardabasso (University Hospital Policlinico Vittorio Emanuele of Catania); Domenica Matranga (University of Palermo); Giuseppe Vita and Stefania 
Mondello (University of Messina); Ferdinando D’Amico (Provincial Health Agency of Messina); Giovanni Sotgiu (University of Sassari)
CORRESPONDING AUTHOR: Prof. Dario Gregori, Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac Thoracic and Vascular 
Sciences, Via Loredan, 18, 35121 Padova – Italy - Phone: +39 049 8275384, Fax: +39 027 00445089, Email: dario.gregori@unipd.it
DOI: 10.2427/12939
Accepted on July 16, 2018
e12939-1
ORIGINAL ARTICLESEpidemiology Biostatistics and Public Health - 2018, Volume 15, Number 3
The NEBICE survey
INTRODUCTION
At the European level the Ethics Committee (EC) 
is defined according to the Directive 2001/20/EC 
of the European Parliament and of the Council as 
“an independent body in a Member State, consisting 
of healthcare professionals and non-medical members, 
whose responsibility it is to protect the rights, safety and 
well-being of human subjects involved in a trial and to 
provide public assurance of that protection, by, among 
other things, expressing an opinion on the trial protocol, 
the suitability of the investigators and the adequacy of 
facilities, and on the methods and documents to be used to 
inform trial subjects and obtain their informed consent” [1].
Even if the European directive has been implemented 
differently in the European countries [2], it was intended 
to “harmonize the administrative provisions governing such 
trials by establishing a clear, transparent procedure and 
creating conditions conducive to effective coordination 
of such clinical trials in the Community by the authorities 
concerned” [1].
In the Italian context, up to 1998, all experimental 
studies had to be regulated, reviewed and approved 
at a national level by a Central Drug Committee 
(Commissione Unica del Farmaco). By Ministerial Decree 
(MD) 15/7/1997 [3] and MD 18/3/1998 [4], the 
responsibility for monitoring and approving clinical trials 
was transferred from the national level of the Ministry of 
Health to local ECs [5]. Unfortunately, such deregulation 
in Italy resulted in an overly heterogeneous evaluation of 
clinical studies by the local ECs and a lack of guidance 
from the top level, with variations in the type of functions 
and types of competence [6-9]. 
According to MD 18/3/1998, Italian EC is 
typically composed of two clinicians, a biostatistician, a 
pharmacologist, a pharmacist, the medical director (or 
scientific director in case of research centers), an legal 
expert, a general practitioner, a bioethicist, a nurse and 
a volunteer for the care of patients or a patient advocacy 
organization [4]. This choice appears as a right balance 
between clinicians and non-clinicians. It is worth noting 
that with the approval of a new Italian law about ECs, 
i.e., MD 12/5/2006 [10], partially modified by the 
MD 07/11/2008 [11], there has been more significant 
involvement of pharmacologists and biostatisticians 
[12]. For instance, before the implementation into Italian 
law of Directive 2001/20/EC by Legislative Decree 
24/6/2003 [13] 32 biostatisticians were working in the 
ECs because their presence was not mandatory [14].
More recently the MD 19/04/2018 [15] established 
the National Coordination Center for the Territorial Ethical 
Committees for clinical trials on medicinal products for 
human use and on medical devices, with no substantial 
change to the composition of ECs but reducing their 
number in Italy, with a specific aim to expediting and 
reducing variation in processing of trial applications.
The new European regulation (Regulation EU N. 
536/2014) remains in the background of this complicated 
regulatory environment, since after being issued in 2014, 
at the time of writing there are still no certainties as to when 
it will come into force in Italy.
Given the heterogeneity in the work of Italian 
ECs [16], a survey was carried out by the Network of 
Biostatisticians in the Ethics Committee (NEBICE), with 
the aim i) to depict the profile of biostatisticians working 
in the ECs, ii) to promote a connection between them by 
means of an internet-based network, and iii) to determine 
the need for targeted professional development, education 
programs, and training. 
The present report illustrates NEBICE survey results 
and offers some remarks.
Facets of Evidence and Ethics in Clinical Research
It has been observed that clinical research can be 
considered ethical if the following conditions are fulfilled 
(even if there can be exceptions in particular circumstances): 
(a) social or scientific value; (b) scientific validity; (c) fair 
subject selection; (d) favourable risk-benefit ratio; (e) 
independent review; (f) informed consent; (g) respect for 
enrolled subjects [17,18]. More generally a trial submitted 
to an EC must feature, to be approved, a rigorous 
methodology, clinical relevance and appropriate principles 
of ethics directed towards patients, society and researchers 
(19). Notably, some ethical and methodological issues 
need to be handled with particular relevance by ECs, 
namely: the appropriateness concerning placebo use 
for the control group, the nature of the comparator, the 
equivalence or non-inferiority design hypothesis of the trial 
and the choice of study endpoints [20]. ECs should require 
systematic reviews of existing research to avoid redundant 
and non-inferior studies [21] and to guarantee the clinical 
equipoise [22]. However, there is no consensus in the 
bioethical community on the justification of the principle of 
clinical equipoise for the moral acceptability of conducting 
a new trial [23,24].
As stated centuries ago by Avicenna, when evaluating 
clinical research, we have to wonder: do I believe the 
data presented? Can I use the results for my patients? 
[25]. It is also essential that the findings of the biomedical 
research have public dissemination since it is ethical 
to share medical knowledge with colleagues and lay 
people [26]. In the past, there has been a substantial 
request for training programs from the members of the 
EC to appropriately deal with local needs. Many Italian 
local ECs are overloaded because of the high number of 
protocols that every year are submitted to them, even if 
only a small part of protocols concern innovative research, 
and there are many differences among the ECs in the 
country [19]. Heterogeneity exists in Europe regarding the 
number of ECs, number of EC members [27], and training 
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requirements. As to the latter, the following topics related 
to training for EC members have been proposed [28]: (a) 
the purpose and history of medical research, (b) the history 
of research ethics, (c) working together in the modern 
regulatory environment, (d) basic ethical principles, (e) 
critical appraisal of a project, (f) ethical analysis, (g) group 
working, (h) reaching consensus, (i) fraud and misconduct. 
Also, it has been noted that there are some negative 
aspects related to ECs, namely: extreme bureaucracy 
[29], late decisions and lack of interest in the decision 
process on genuine bioethical issues. 
Ethical evaluation of a study by an EC requires 
on the part of at least a majority of members, a sound 
knowledge of Evidence-Based Medicine principles (EBM) 
and functional competence in biostatistical methods, since 
it is unethical to conduct research that is unsound, for they 
can improperly modify medical evidence on a particular 
issue, and this may ensue many ethical problems [30]. 
Clinicians are mainly concerned with the ethical issues 
related to the health of their present patient while, in 
addition to that, the members of the ECs need to treat and 
evaluate all ethical questions which arise from a study, 
in order to warrant the safety of a drug or treatment also 
for future patients [31]. Thus, the interplay between an 
individual level of ethics and a collective one is required 
and desirable. Moreover, many other ethical constraints 
are related to medical research: it is not ethical to deprive 
patients of useful treatment, as well as it is necessary to 
stop a trial when there is sufficient evidence of no clinical 
significance of treatment in order not to expose patients to 
useless risks. 
It has been observed, in fact, that the scientific 
evaluation of a trial or a treatment is a necessary, but not 
a sufficient, condition for a sound ethical evaluation [30]. 
Many errors can be associated with clinical research: 
poor definition of the research question, of the inclusion 
and exclusion criteria, wrong determination of the sample 
size, failure of a suitable control group, failure to carry 
out the study objectively, failure to evaluate the results 
of the subjects withdrawn from the study or to comment 
them in the study [32,33]. Also, it has been claimed that 
“a valuable attribute of statisticians is their ability to ask 
relevant and important questions, not only about statistical 
issues but also about the purpose of the research” [34]. 
Conversely, all the other members of the EC should also 
have a basic knowledge of medical statistics and of the 
many forms of bias which may affect clinical and statistical 
judgment [35,36].
METHODS
The survey was launched in early November 2016, 
and data were collected until August 2017. An e-mail 
survey invitation was sent to all secretaries of the 95 Italian 
ECs contained in the registry of the National Monitoring 
Center on Clinical Research with Medicines (Osservatorio 
Nazionale sulla Sperimentazione Clinica dei Medicinali) 
maintained by the Italian Agency of Medicines (AIFA) as 
updated at September 2016.
The survey was created within an electronic data 
capture system hosted at University of Padova and known as 
REDCap (Research Electronic Data Capture) [37]. REDCap 
is a secure, web-based application designed to support 
data capture for research studies, developed initially at 
Vanderbilt University (https://projectredcap.org).
The interested EC biostatisticians were able to access 
the survey anonymously via a request for use through the link 
(https://redcap.dctv.unipd.it/surveys/?s=X89348XXFY) 
contained in the survey invitation. Several aspects 
were explored including education, job title, training 
in biostatistics and personal experience in protocol 
evaluation within the EC. 
The type of institution where the ECs observed do 
operate, were classified as LHA=local health authority; 
Hospital=local hospital; IRCCS=public or local private 
hospital with a research mission acknowledged by the 
Italian Ministry of Health; University = teaching hospital of 
a State or Private University.
Data were analyzed with R software version 3.2.5  [38].
RESULTS
The investigation covered 95 ECs in Italy, and 70 
questionnaires were returned, yielding a 74% response 
rate. The response rate varied by geographical location 
(Northern, Center and Southern Italy), with a 78% 
compliance for ECs in the South versus 51% for those 
located in the North, and by type of institution in which the 
examined ECs operate. 
The biostatisticians in the respondent ECs were 
prevalently male (n=41,59%), between 50 and 60 years 
of age (n=30, 43%) and 39 were not affiliated with the 
facility in which the EC operates. For 42 of them (60%), 
the highest academic degree was Ph.D. or postgraduate 
specialty (46 academic degrees, overall). Among Ph.D. 
fields, the most common was epidemiology (43%). Among 
postgraduate specialties, the most frequent was in health/
medicine (69%) followed by specialty in statistics (see 
Table 1). This distribution exhibits geographical variation, 
being statistics the most common specialty in the North and 
health/medicine the most common specialty in the South. 
The self-reported best level of statistical training, relevant 
to EC activity (i.e. descriptive, inferential and medical 
statistics, clinical epidemiology, …) was mainly achieved 
through short courses, from 27% to 47% (depending on 
the topic) and courses in specialty programs, from 15% to 
25%, whereas courses in Ph.D. programs contributed to a 
lower extent (from 9% to 18%). The practical knowledge of 
statistics was measured by the frequency with which the EC 
biostatistician analyses data (categorized as always, never, 
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sometimes). Its distribution by type of data and geographical 
location of the EC is shown in Table 2. 
Concerning the scientific activity, the median number 
of publications of the EC biostatistician, in the last five 
years on indexed journals, ranged from 4 to 46, for 
hospitals and university ECs, respectively. Regardless of 
the institution and the geographical location of the ECs, 
76% of biostatisticians declared to be involved in research 
activities and 70% in teaching activities.
The annual workload for the EC members varied by 
the type of institution and geographical area. The median 
number of examined protocols per year ranged from 80 
in hospital ECs to 198 in university ECs, and from 80 to 
108, in the South and the Centre, respectively. About 40% 
of these protocols concerned observational studies.
As for the evaluation of protocols, the study design and 
objectives, together with statistical issues were identified as 
the most relevant aspects to be taken into account. The 
handling of missing data and economic aspects were 
regarded as less important (see Table 3, panel A). When 
asked to rank the principal motivations for a protocol 
rejection, an unethical treatment or aspects related to the 
sample size were given high importance (Table 3, panel 
B). Sample size calculation equally influenced protocol 
suspension and rejection (Table 3, panels B-C). 
Although an EC decision on a research protocol is 
made by consensus, a question on the individual opinion 
of the EC biostatistician was included in the survey. The 
proportion of protocols that were not approved by the 
EC biostatistician did not appear to depend on the type 
of institution in which the EC was set and the affiliation 
of the principal investigator, except for the suspension of 
protocols in university ECs (Table 4). 
Overall, the biostatistician proposed to reject 5% 
of the protocols and to suspend with the request for 
clarification or amendments 10%. About 61% and 79% of 
these opinions, respectively, were regarded as binding by 
the other EC members in reaching a decision. It is worth 
noting that EC biostatisticians older than 45 years (n=30, 
29 missing answers) were taken into greater consideration 
when proposing to reject a protocol. 
In evaluating a protocol, 58% of EC biostatisticians 
declared to consult supplementary material (i.e., textbooks, 
online databases). This proportion was higher in the North 
(70%) and lower in the South (33%). As to the time spent, 
40% of protocols were examined in 16-30 minutes, but 
variability exists between the different types of institutions 
that host the EC (Table 5). 
Concerning the implementation of training, education 
and information programs for EC biostatistician, 18 
declared that their EC did not provide for continuing 
education opportunities, never promoted courses on 
TABLE 1. Distribution of PhD or post-graduate specialty as highest academic degree, obtained by the EC biostatistician by type of 
institution in which the EC operates. 
LHA Hospital IRCCS University Total
N % N % N % N % N %
Specialty
Statistics 2 13.3 3 33.3 3 60.0 8 25.0
Medical/Health 3 100.0 13 86.7 4 44.0 2 40.0 22 68.8
Epidemiology 2 22.2 2 6.3
PhD
Statistics 1 50.0 1 25.0 2 40.0 1 33.3 5 35.7
Medical/Health 2 40.0 1 33.3 3 21.4
Epidemiology 1 50.0 3 75.0 1 20.0 1 33.3 6 42.9
Legend: LHA Local Health Authority; IRCCS Research Clinical Institute
TABLE 2. Practical knowledge in data analysis by type of data and geographical location of the EC (15 missing answers).
North Centre South
Total %
N % N % N %
Analysis of non-biomedical data 
always 10 35.7 2 16.7 7 43.8 19 33.9
sometimes 9 32.1 3 25.0 5 31.3 17 30.4
never 9 32.1 7 58.3 4 25.0 20 35.7
Analysis of data from 
experimental studies 
always 15 53.6 7 63.6 12 75.0 34 61.8
sometimes 12 42.9 4 36.4 4 25.0 20 36.4
never 1 3.6     1 1.8
Analysis of data from 
epidemiological/observational 
studies
always 20 71.4 9 75.0 15 93.8 44 78.6
sometimes 7 25.0 3 25.0 1 6.3 11 19.6
never 1 3.6     1 1.8
Analysis of other biomedical 
data 
always 8 29.6 6 50.0 9 56.3 23 41.8
sometimes 14 51.9 5 41.7 5 31.3 24 43.6
never 5 18.5 1 8.3 2 12.5 8 14.6
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research methodology (n=20) but regularly informed on 
regulatory aspects (n=24).
When asked whether his/her skills and experience fit 
the position of EC biostatistician (on a 0 -100 scale), the 
median self-perceived adequacy was good, ranging from 
70 for LHA ECs to 90 for hospital ECs.  
DISCUSSION
Italian ECs have the responsibility for evaluating and 
monitoring clinical studies in human subjects, with the 
ultimate goal to promote high ethical standards in research 
for health [19, 39]. 
The NEBICE study was intended to provide an 
outline of the characteristics and activities carried out 
by the biostatisticians in the Italian ECs, to identify the 
best strategies to promote methodological rigor and 
ethical behavior. Although the survey was not aimed at 
an evaluation of quality and workload of ECs, it offered 
an intriguing insight into the operation of the clinical trial 
regulations in Italy, and a perspective which is different, 
albeit complementary, from that recorded by AIFA in 
its annual Bulletin (http://www.aifa.gov.it/en/content/
bulletin-clinical-trials-drugs-italy). 
To our knowledge, NEBICE is the study which 
involves the highest number of Italian ECs.
In our investigation, we mainly focused on the ethical 
TABLE 3. Frequency of ranks attributed by the EC biostatistician to some aspects in the evaluation of a protocol (panel A) and in a 




1 2 3 4 5 6 7 8 9 10
Rationale 34.7 8.2 12.2 4.1 4.1 4.1 12.2 8.2 2.0 10.2
Study Objectives 42.9 16.5 2.0 2.0 2.0 2.0 2.0 6.1 14.3 10.2
Study Design 44.9 10.2 6.1 2.0 2.0 0.0 0.0 6.1 4.1 24.6
Sample Size calculation 38.8 8.2 8.2 2.0 4.1 0.0 6.1 4.1 12.2 16.3
Statistical analysis of primary endpoints 34.7 8.2 8.2 6.1 2.0 6.1 0.0 10.2 6.1 18.4
Statistical analysis of secondary endpoints 14.3 8.2 14.3 8.2 10.2 12.1 8.2 4.1 6.1 14.3
Treatment of missing data 10.4 16.8 6.2 12.5 6.2 12.5 6.2 18.8 6.2 4.2
Informed Consent 24.5 12.2 6.1 4.1 8.2 6.1 10.2 8.2 4.1 16.3
Insurance Issues 20.3 14.3 6.1 4.1 8.2 6.1 8.2 4.1 10.2 18.4




1 2 3 4 5 6 7 8 9 10
Rationale 7.0 18.5 9.3 11.6 11.6 14.0 4.7 14.0 9.3 0.0
Study Objectives 25.0 27.2 11.4 2.3 2.3 2.3 4.5 6.8 18.2 0.0
Study Design 20.9 34.9 11.6 2.3 0.0 0.0 4.7 9.3 16.3 0.0
Unethical Treatment 26.7 9.8 4.9 4.9 9.8 4.9 9.8 12.1 17.1 0.0
Sample Size 27.5 17.5 10.0 0.0 5.0 2.5 5.0 15.0 17.5 0.0
Statistical Analysis 20.9 18.5 7.0 11.6 2.3 4.7 16.3 4.7 14.0 0.0
Informed Consent 11.9 11.9 7.2 19.0 11.9 7.1 7.1 4.9 19.0 0.0




1 2 3 4 5 6 7 8 9 10
Rationale 3.0 22.8 12.9 7.9 9.9 7.9 7.9 12.9 14.8 0.0
Study Objectives 20.2 28.2 15.2 2.0 0.0 5.1 2.0 5.1 22.2 0.0
Study Design 32.6 17.8 12.9 3.0 0.0 0.0 3.0 12.9 17.8 0.0
Unethical Treatment 20.8 7.9 5.0 10.9 10.9 0.0 10.9 15.8 17.8 0.0
Sample Size 29.0 22.0 10.0 5.0 0.0 0.0 5.0 7.0 22.0 0.0
Statistical Analysis 24.2 19.2 14.1 5.1 7.1 2.0 0.0 7.1 21.2 0.0
Informed Consent 22.2 10.1 20.2 8.1 10.1 5.1 2.0 2.0 20.2 0.0
Insurance 15.0 15.0 8.0 8.0 13.0 3.0 5.0 10.0 23.0 0.0
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and methodological issues that a biostatistician in an EC 
may ordinarily encounter. We observed that the role of 
the biostatistician in the Italian ECs is multifaceted. Only 
a few of them have a Ph.D. degree while the most part 
has postgraduate education in medical specialties. Also, it 
is quite remarkable that other EC members do not hold in 
enough regard the contrary opinion of the biostatistician.  
The biostatistician will not play a significant role in the 
EC as long as the requirements that an individual has to 
fulfill to be a biostatistician in an EC remain vague and, 
his/her opinion is not binding for the judgment of approval 
or refusal of a protocol. 
This fact may also entail severe ethical problems, as 
a valid quantitative approach to research is a requirement 
for complete ethical evaluation of a protocol.
More generally, there is a lack of understanding of 
the intimate connection between biostatistics and ethics. 
Biostatistics must not be conceived as a value-free science 
since the ethical consequences of making a statistically 
wrong decision have to be taken into account [40,41]. 
The evaluation of a research protocol involves many 
biostatistical issues which present some intricate ethical 
counterparts. Given that there is such a strict relationship 
between ethics and methodology in ECs, the role of the 
biostatistician should be enriched with more comprehensive 
and interdisciplinary training to be capable of acting in 
response to the new challenges of the innovations in the 
biomedical sciences. 
It is fundamental to pinpoint the mandatory 
competencies that the biostatistician of ECs should have, to 
guarantee standardization, fairness, and rigor in protocol 
evaluation, ultimately increasing the level of competence 
as new challenges, and new study designs arise [42-44]. 
Professional certification through organizations that establish 
credible and robust certification systems, incorporating 
requirements of the continuance of certification (i.e., to 
ensure that a certificate holder continues to learn and 
stay up to date in the practice field) might accomplish this 
task. Nevertheless, the need for professional certification 
of biostatisticians is still a matter of debate in the Italian 
scientific community. 
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